Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 874.7% from a year ago
Total equity stood at $218.73M at the end of Q1 FY2026, up 874.7% from a year earlier and up 152.8% from the prior quarter. Over 3 fiscal years it compounded at -14.9% a year.
Context
- Total equity amounted to 92.9% of total assets at the end of Q1 FY2026, up 11.9 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +874.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 86.51M USD
- Year-over-year change
- +143.5%
- 4-year CAGR
- -19.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 86.51M | +143.5% |
| FY2024 | 2024-12-31 | 35.52M | -58.4% |
| FY2023 | 2023-12-31 | 85.36M | -39.2% |
| FY2022 | 2022-12-31 | 140.44M | -32.6% |
| FY2021 | 2021-12-31 | 208.26M | — |
Total Equity vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's Mar 2026 total equity of $218.73M is the highest of the 9 companies compared; the peer median is $96.22M.
- Its year-over-year change of +874.7% is the 2nd highest of 9, against a peer median of -26.8%.
- Total equity amounts to 92.9% of total assets for RLMD, versus a peer median of 68.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $218.73M | +874.7% | -14.9% | 92.9% | |
| Mar 2026 | $202.37M | +523.0% | +7.5% | 56.7% | |
| Mar 2026 | $151.23M | +2960.5% | — | 79.7% | |
| Mar 2026 | $140.07M | -13.2% | -18.3% | 82.7% | |
| Mar 2026 | $96.92M | -53.9% | +7.4% | 48.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $95.52M | -40.4% | -12.9% | 88.6% |
| Mar 2026 | $94.12M | +106.3% | -7.4% | 52.3% | |
| Mar 2026 | $87.97M | -45.1% | -24.8% | 91.1% | |
CBUSCibus, Inc. | Mar 2026 | $35.48M | -52.0% | +44.5% | 10.9% |
| Peer median (excluding RLMD) | $96.22M | -26.8% | -7.4% | 68.2% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 44.44M | 5.4M | 4.09M | 3.86M | 3.5M |
| Short-term Investments | 167.47M | 142.93M | 92.23M | 41.05M | 89.51M |
| Net Receivables | 86.38K | 512.43K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 35 | 0 | 0 | 0 | 0 |
| Total Current Assets | 223.3M | 152.87M | 97.51M | 45.8M | 93.98M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 28.29K | 34.88K | 43.13K | 21.98K | 19.5K |
| Total Non-current Assets | 28.29K | 34.88K | 43.13K | 21.98K | 19.5K |
| Total Assets | 223.33M | 152.91M | 97.55M | 45.82M | 94M |
| Account Payables | 11.19M | 5.26M | 3.51M | 4.13M | 1.57M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.64M | 1.02M | 5.68M | 1.15M | 535.48K |
| Total Current Liabilities | 15.06M | 12.47M | 12.19M | 10.29M | 6.43M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 4.47K | 1.06M |
| Total Non-current Liabilities | 0 | 0 | 0 | 4.47K | 1.06M |
| Total Liabilities | 15.06M | 12.47M | 12.19M | 10.3M | 7.49M |
| Common Stock | 27.74K | 30.1K | 30.1K | 30.17K | 73.33K |
| Retained Earnings | (305.07M) | (462.11M) | (560.9M) | (640.88M) | (698.27M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 208.26M | 140.44M | 85.36M | 35.52M | 86.51M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (44.44M) | (5.4M) | (4.09M) | (3.86M) | (3.5M) |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.